Portfolio

SkinJect_72

A novel drug delivery using a dissolvable microneedle array that would both treat – and potentially prevent the recurrence of – basal cell and squamous cell skin cancer. SkinJect will offer an effective way to eliminate existing non-melanoma skin cancers while potentially preventing recurrence as well as providing a safe, convenient way to deliver therapy.

Sector: Drug Delivery

Year Funded: 2016

InClinica_2c

A global, clinical CRO that leads companies through clinical trials, with a special strength assisting small to mid-sized companies that are entering first-in-man and phase two trials. InClinica’s senior leadership team has extensive experience in drug development and clinical trial management and brings access to world-class experts who are critical to trial design and execution.

Sector: Medical Services

Year Acquired: 2016